Compare SKY & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKY | ACAD |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.2B |
| IPO Year | N/A | 2004 |
| Metric | SKY | ACAD |
|---|---|---|
| Price | $84.32 | $26.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 21 |
| Target Price | ★ $85.00 | $29.24 |
| AVG Volume (30 Days) | 717.0K | ★ 1.5M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 48.48 | ★ 98.53 |
| EPS | ★ 3.84 | 1.54 |
| Revenue | ★ $2,624,539,000.00 | $1,047,118,000.00 |
| Revenue This Year | $5.10 | $15.16 |
| Revenue Next Year | $4.21 | $11.42 |
| P/E Ratio | $21.76 | ★ $17.26 |
| Revenue Growth | 12.14 | ★ 12.69 |
| 52 Week Low | $59.44 | $13.40 |
| 52 Week High | $116.49 | $26.75 |
| Indicator | SKY | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 60.64 | 73.30 |
| Support Level | $75.94 | $22.81 |
| Resistance Level | $87.17 | $25.20 |
| Average True Range (ATR) | 2.83 | 0.86 |
| MACD | 0.17 | 0.25 |
| Stochastic Oscillator | 73.25 | 98.98 |
Champion Homes Inc is a factory-built housing company in North America. The company is well positioned with an portfolio of manufactured and modular homes, ADUs, park-models and modular buildings for the single-family, multi-family, and other hospitality sectors. In addition to its core home building business, the company provides construction services to install and set-up factory-built homes, operates a factory-direct retail business with 72 retail locations across the United States, and operates Star Fleet Trucking, providing transportation services to the manufactured housing and other industries from several dispatch locations across the United States.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.